 |
|
|
| |
Treatment with GSK3228836 leads to HBsAg reduction
and induction of interferon gamma related proteins
and chemokines in a Phase 2a, randomized,
double-blind, placebo-controlled study
|
| |
| |
EASL International Liver Congress, June 23-26, 2021
Shihyun You1, Jennifer Singh1, Susan Smith1, William Jordan1, Katja Remlinger2, Shilpy Joshi1, Megan Ermler1, Jared Delahaye1, Adam Taylor3, Sutirtha Chakraborty4, Dhyanesh Srivastava5, Melanie Paff1, Dickens Theodore2
1GlaxoSmithKline, Collegeville, PA, USA; 2GlaxoSmithKline, Research Triangle Park, NC, USA; 3GlaxoSmithKline, Stevenage, UK; 4GlaxoSmithKline, Bangalore, India; 5GlaxoSmithKline, Noida, India
|
| |
|
|
|
|
|
